Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

DAU9
505320
DASM4
60553
Results of this test are confirmed and should be considered definitive. Specimens are normally kept for
2 weeks after Mayo Medical Laboratories New England receipt date.
Clinical References: Porter WF, Moyer TP: Clinical toxicology. In Tietz Textbook of Clinical
Chemistry. Fourth edition. Edited by CA Burtis, ER Ashwood. Philadelphia, PA, WB Saunders Company,
1993, pp 1155-1235
Drugs of Abuse Screen, DAU9, Urine
Clinical Information: This test uses immunologic testing for drugs by class and screens for the
presence of amphetamines, barbiturates, benzodiazepines, cocaine, metabolite, methadone, opiates,
phencyclidine, propoxyphene, and tetrahydrocannabinol in urine. Positive immunologic results are
confirmed by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass
spectrometry (LC-MS/MS).
Useful For: Detecting drug abuse involving amphetamines, barbiturates, benzodiazepines, cocaine,
opiates, phencyclidine, tetrahydrocannabinol, methadone, and propoxyphene This test is intended to be
used only by a qualified drug treatment counselor or physician.
Interpretation: A positive result indicates that the patient has used the drugs detected in the recent
past. For information about drug testing, including estimated detection times, see Drugs of Abuse Testing
at http://www.mayomedicallaboratories.com/articles/drug-book/index.html Creatinine and specific gravity
are measured as indicators of specimen dilution.
Reference Values:
Negative
The specific drug identified will be reported.
EMIT cutoff concentrations
Amphetamines: 500 ng/mL
Barbiturates: 200 ng/mL
Benzodiazepines: 200 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Methadone: 300 ng/mL
Opiates: 300 ng/mL
Phencyclidine: 25 ng/mL
Propoxyphene: 300 ng/mL
THC: 50 ng/mL
Results of this test are confirmed and should be considered definitive. Specimens are normally kept for 2
weeks after Mayo Medical Laboratories New England receipt date.
Clinical References: Porter WF, Moyer TP: Clinical toxicology. In Tietz Textbook of Clinical
Chemistry. Fourth edition. Edited by CA Burtis, ER Ashwood. Philadelphia, WB Saunders Company,
1993, pp 1155-1235
Drugs of Abuse Screen, Meconium 4
Clinical Information: Illicit drug use during pregnancy is a major social and medical issue. Drug
abuse during pregnancy is associated with significant perinatal complications, which include a high
incidence of stillbirths, meconium-stained fluid, premature rupture of the membranes, maternal
hemorrhage (abruption placenta or placenta praevia), and fetal distress.(1) In the neonate, the mortality
rate, as well as morbidity (eg, asphyxia, prematurity, low birthweight, hyaline membrane distress,
infections, aspiration pneumonia, cerebral infarction, abnormal heart rate and breathing problems, drug
withdrawal) are increased.(1) The disposition of drug in meconium is not well understood. The proposed
mechanism is that the fetus excretes drug into bile and amniotic fluid. Drug accumulates in meconium
either by direct deposit from bile or through swallowing of amniotic fluid.(2) The first evidence of
meconium in the fetal intestine appears at approximately the 10th to 12th week of gestation, and slowly
moves into the colon by the 16th week of gestation.(3) Therefore, the presence of drugs in meconium has
Current as of January 3, 2013 2:22 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 648